Progen Biotechnik Inks Deals for Assay Distribution, Development | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German firm Progen Biotechnik today announced an exclusive distribution agreement covering Germany with Asuragen to offer multiplexed assays based on Asuragen technology.

As a result of the deal, Progen can now offer assays incorporating Asuragen's Signature technology for the detection of mutations found in solid tumors, such as KRAS and BRAF, and fusion transcripts or mutations associated with specific leukemia types and subtypes, Progen said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.